[ node.tpl : 'full']
Breakthrough Breast Cancer comments on NICE’s (the National Institute for Health and Clinical Excellence) decision to open a consultation on new, draft guidance which does not recommend bevacizumab (Avastin) for the first-time treatment of metastatic breast cancer, when used in combination with the chemotherapy drug, capecitabine.
Dr Rachel Greig, Senior Policy Officer at Breakthrough Breast Cancer, said:
"We welcome new treatments for women with metastatic breast cancer as we know their options are limited and prolonging life is incredibly important to them and their families. However, this treatment combination can cause serious side effects and there is no evidence to show how this may affect a patient’s quality of life.”